Product Description
PF-03654764 should reduce the symptoms of allergic rhinitis (Sourced from: https://www.clinicaltrials.gov/ct2/show/NCT01033396)
Mechanisms of Action: H3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Rhinitis, Allergic
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01298505 |
B0711006 | P1 |
Terminated |
Healthy Volunteers |
2010-06-04 |
2019-03-19 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments |
|
NCT00989391 |
B0711002 | P1 |
Completed |
Healthy Volunteers |
2009-12-01 |
2019-03-19 |
||
NCT01033396 |
B0711005 | P2 |
Completed |
Rhinitis, Allergic |
2010-05-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|